PRCTC
a machine learning model for prediction of response to corticosteroid therapy in COVID-19 patients
Gao, Yue; Xiong, Xiaoming; Jiao, Xiaofei; Yu, Yang; Chi, Jianhua; Zhang, Wei; Chen, Lingxi; Li, Shuaicheng; Gao, Qinglei

Published in:
Aging

Published: 15/01/2022

Document Version:
Final Published version, also known as Publisher’s PDF, Publisher’s Final version or Version of Record

License:
CC BY

Publication record in CityU Scholars:
Go to record

Published version (DOI):
10.18632/aging.203819

Publication details:
Gao, Y., Xiong, X., Jiao, X., Yu, Y., Chi, J., Zhang, W., Chen, L., Li, S., & Gao, Q. (2022). PRCTC: a machine learning model for prediction of response to corticosteroid therapy in COVID-19 patients. Aging, 14(1), 54-72. https://doi.org/10.18632/aging.203819

Citing this paper
Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights
Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.

Publisher permission
Permission for previously published items are in accordance with publisher's copyright policies sourced from the SHERPA RoMEO database. Links to full text versions (either Published or Post-print) are only available if corresponding publishers allow open access.

Take down policy
Contact lbscholars@cityu.edu.hk if you believe that this document breaches copyright and provide us with details. We will remove access to the work immediately and investigate your claim.
PRCTC: a machine learning model for prediction of response to corticosteroid therapy in COVID-19 patients

Yue Gao1,2,*, Xiaoming Xiong1,2,*, Xiaofei Jiao1,2, Yang Yu1,2, Jianhua Chi1,2, Wei Zhang1,2, Lingxi Chen3,8, Shuaicheng Li3, Qinglei Gao1,2

1Cancer Biology Research Center, Key Laboratory of Chinese Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
2Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
3Department of Computer Science, City University of Hong Kong, Kowloon Tong 999077, Hong Kong
*Equal contribution

Correspondence to: Wei Zhang, Lingxi Chen, Shuaicheng Li, Qinglei Gao; email: zhangwei_tjh@qq.com, https://orcid.org/0000-0001-8068-9386; chanlingxi@gmail.com; shuaicli@cityu.edu.hk; qingleigao@hotmail.com, https://orcid.org/0000-0002-9448-3423

Keywords: COVID-19, corticosteroid, machine learning, lymphocyte percent, C reactive protein

Received: September 27, 2021 Accepted: December 25, 2021 Published: January 12, 2022

Copyright: © 2022 Gao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Corticosteroid has been proved to be one of the few effective treatments for COVID-19 patients. However, not all the patients were suitable for corticosteroid therapy. In this study, we aimed to propose a machine learning model to forecast the response to corticosteroid therapy in COVID-19 patients. We retrospectively collected the clinical data about 666 COVID-19 patients receiving corticosteroid therapy between January 27, 2020, and March 30, 2020, from two hospitals in China. The response to corticosteroid therapy was evaluated by hospitalization time, oxygen supply duration, and the outcomes of patients. Least Absolute Shrinkage and Selection Operator (LASSO) was applied for feature selection. Five prediction models were applied in the training cohort and assessed in an internal and an external validation dataset, respectively. Finally, two (C reactive protein, lymphocyte percent) of 36 candidate immune/inflammatory features were finally used for model development. All five models displayed promising predictive performance. Notably, the ensemble model, PRCTC (prediction of response to corticosteroid therapy in COVID-19 patients), derived from three prediction models including Gradient Boosted Decision Tree (GBDT), Neural Network (NN), and logistic regression (LR), achieved the best performance with an area under the curve (AUC) of 0.810 (95% confidence interval [CI] 0.760–0.861) in internal validation cohort and 0.845 (95% CI 0.779–0.911) in external validation cohort to predict patients’ response to corticosteroid therapy. In conclusion, PRCTC proposed with universality and scalability is hopeful to provide tangible and prompt clinical decision support in management of COVID-19 patients and potentially extends to other medication predictions.

INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], has become a global pandemic and brought a heavy burden on health care around the world. As of December 10, 2021, SARS-CoV-2 has led to more than 265 million infections and over five million deaths in 223 countries and territories [2]. Mild COVID-19 patients are often accompanied by fever, cough, and myalgia. However, acute respiratory distress syndrome (ARDS)...
and multiple organ failure (MOF) are common in severe and critical patients, contributing to the principal cause of death in COVID-19 [3]. A previous study has reported that immune dysregulation and inflammatory cytokines storm played important roles in ARDS and MOF in COVID-19 patients [4]. It is acknowledged that once entering into cells, SARS-CoV-2 will trigger antiviral responses of the hosts' innate and adaptive immunity [5]. For example, numerous immune and inflammatory cells are activated and produce various proinflammatory cytokines, termed cytokine storms. These cytokines will further induce tissue damage which contributes to more production of cytokines in turn. This positive feedback loop finally gives rise to ARDS and MOF [6]. Thus, anti-inflammatory/immunomodulatory therapy may be beneficial especially for severe and critical COVID-19 patients.

Corticosteroid, a kind of affordable, nonspecific anti-inflammatory, and immunomodulatory drug, has been widely applied to treat COVID-19 patients. However, the effect of corticosteroid therapy is an enduring controversy, especially in critical COVID-19 patients [7, 8]. Several published clinical trials revealed that administration of systemic corticosteroids was associated with a lower 28-day mortality compared with usual care or placebo in these patients [9, 10]. But some other studies demonstrated corticosteroid therapy delayed viral clearance [11, 12], cause a secondary infection [13], and prolonged the duration of hospitalization in COVID-19, middle east respiratory syndrome, and influenza pneumonia [14]. The controversy was principally attributed to the question that it was unclear who can benefit from corticosteroid therapy. Cai et al. found corticosteroid treatment in patients with neutrophil-to-lymphocyte ratio > 6.11 at admission was accompanied by a lower risk of 60-day all-cause mortality. However, they did not systematically screen the factors which might be associated with the efficiency of corticosteroid therapy. And it was unknown whether any other features could predict the efficiency of corticosteroid therapy [15]. Thus, it would make sense to investigate more indicators to guide the corticosteroid use in COVID-19 patients.

Statistical modeling and machine learning algorithms have potential performance in the diagnosis, treatment, prediction of epidemic development, and outcome of COVID-19 patients [16]. There were some models for discovering and repurposing drugs suitable for combating COVID-19 [17, 18]. However, the computational models to help decision-making on precision medication of COVID-19 are currently not available. Given the puzzles of targeting responders to corticosteroid therapy in COVID-19 and the superiority of machine learning, we aim to develop a model to help clinicians identify the patients who will benefit from corticosteroid therapy.

MATERIALS AND METHODS

Cohort study design

All COVID-19 patients from two hospitals (Sino-French New City Campus of Tongji Hospital, SF; Optical Valley Campus of Tongji Hospital, OV) between January 27, 2020, and March 30, 2020, were diagnosed according to the Diagnosis and Treatment Protocol of COVID-19 published by the National Health Commission of the People’s Republic of China (Trial Version 7) [19]. The electronic health records (EHR) of diagnosed COVID-19 patients were retrospectively reviewed. Patients who received corticosteroid therapy and were with immune/inflammatory laboratory test results at admission were included in our study. Finally, this multicenter, retrospective study included 666 consecutive COVID-19 patients. Hospitalization time, oxygen supply duration, and outcomes were considered together to evaluate response to corticosteroid therapy since these were well-recognized indicators for judging the efficacy of hormone therapy [15, 20]. Selected patients dying in the hospital were straightforwardly determined as non-response to corticosteroids. Considering the longer hospitalization time and oxygen supply duration in critically ill patients, and to avoid the bias of labeling patients caused by this reason, we divided the remaining patients into general, severe, and critical groups according to the Diagnosis and Treatment Protocol of COVID-19 (Trial Version 7) [19]. In each group, patients with hospitalization time and oxygen supply duration below the median of the population were defined as responders. In contrast, patients with hospitalization time or oxygen supply duration no shorter than the median of the population were defined as non-responders. Besides, patients without receiving oxygen treatment were classified based only on hospitalization time. Thus, all the 666 patients with different severities were classified into responders and non-responders accordingly.

We then randomly partitioned 50% and 50% of participants from SF into training cohort and internal validation cohort, respectively. Participants from OV were used as the external validation cohort. Naturally, there were 268 patients in the training cohort, 267 patients in the internal validation cohort, and 131 patients in the external validation cohort.
Data preprocessing and feature selection

To enable this model to inform treatment decision-making, we only selected features that are readily available at admission. Since corticosteroids are involved in the regulation of immune and inflammatory factors, a total of 36 candidate immune/inflammatory laboratory tests were collected from EHRs of patients on admission. Trained researchers entered and double-checked the data independently. Features were excluded if ≥20% of values were missing (Supplementary Figure 1A), which resulted in ten features left for model development (Supplementary Figure 1B). Then, we utilized the missForest [21] algorithm to impute the missing values in each hospital respectively (Supplementary Figure 2). Features selection aimed to optimize the feature group by identifying the smallest independent set of features with the greatest predictive performance and minimize overfitting. We applied LASSO (Least Absolute Shrinkage and Selection Operator) logistic regression to identify the most informative set of features [22] (Figure 1A). LASSO utilizes the L1 penalty to make the coefficients of weak features turn to zero during fitting [23]. We regarded features with zero coefficients as redundant, and only non-zero coefficient features were included for model training (Figure 1B).

Model development and validation

As previously demonstrated [24, 25], we fitted the selected features into five computational prediction models, including Logistic Regression (LR), Support Vector Machine (SVM), Gradient Boosted Decision Tree (GBDT), K-Nearest Neighbor (KNN), and Neural Network (NN), to predict whether patients were responsive to corticosteroid therapy. We selected the five models because of their representativity and popularity in EHR prediction. Besides, they are sensitive to different data modalities. For instance, GBDT model is based on the decision tree, where features are merely used to split the node, thus GBDT is not sensitive to scale and distribution of features [26], which is applicable to KNN as well. Therefore, scaling is not required for GBDT and KNN. LR, SVM, and NN train weights by gradient descent, leading to the sensitivity to feature scales. Thus, standardizing data is required to eliminate the differences between features and accelerate the convergence of model [27]. Patients with predictive probability larger or equal to 0.5 were considered as responders to corticosteroid therapy. Otherwise, patients were

---

Figure 1. The features were selected by LASSO. (A) showed LASSO variable trace profiles of the ten features. The vertical dashed line shows the best lambda value (0.081) chosen by tenfold cross-validation. (B) showed features with zero coefficient (colored with gray) at lambda = 0.081, was considered less crucial to the patient’s response to corticosteroid therapy and removed by Lasso logistic regression analysis. Features with positive coefficient (colored with red) are regarded as positively associated with response to corticosteroid therapy. Features with negative coefficient (colored with blue) are regarded as negatively associated with response to corticosteroid therapy. Abbreviations: LASSO least absolute shrinkage and selection operator; IL-8 interleukin-8; IL-10 interleukin-10; IL-6 interleukin-6; IL-2R interleukin-2 receptor; IL-1β interleukin-1β; TNF-α tumor necrosis factor α; PCT procalcitonin; CRP C reactive protein.
considered as non-responders. To establish the ensemble model, we tested various combinations of baseline models and discovered that the composition of LR, GBDT, and NN with respective weighted voting 0.1, 0.8, and 0.1 delivered the highest AUC. R library “caret” was adopted for model training and prediction with 10-fold cross-validation. The LR, SVM, GBDT, KNN, and NN were run with method “glm,” “svmLinearWeights,” “gbm,” “knn,” and “avNNet” with default settings, respectively. Data were standardized before training and testing. We obtained the feature importance of baseline and ensemble model from R package “caret”.

Statistical analysis

All statistical analysis was conducted with R (version 3.6.2). We obtained the receiver operating characteristics (ROC) curve and AUC analysis with R “pROC” package. We plotted the calibration curve with R “rms” package. We calculated the accuracy (ACC), sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), Cohen’s kappa coefficient (Kappa), F1 score, and Brier score with R “caret,” “epiR,” and “rms” packages. We considered P values less than 0.05 as statistically significant. the ninety-five percent confidence interval (CI) was reported if necessary.

Ethics approval

The study was performed in accordance with the tenets of the Declaration of Helsinki and the Good Clinical Practice principles. This study was approved by the Research Ethics Commission of Tongji Medical College, Huazhong University of Science and Technology (TJIRB202000406) with waived informed consent by the Ethics Commission mentioned above. This study was registered in the Chinese Clinical Trial Registry (ChiCTR2000032161).
Table 1. Baseline clinical characteristics of patients.

| Characteristics                          | Total (N=666) | Training cohort (N=268) | Internal validation cohort (N=267) | External validation cohort (N=131) |
|-----------------------------------------|---------------|-------------------------|-----------------------------------|-----------------------------------|
| Age (years), median (IQR)               | 64 (54–71)    | 64 (54–71)              | 64 (52.5–71)                      | 67 (59–75)                       |
| Sex, n (%)                              |               |                         |                                   |                                   |
| Female                                  | 295 (44.29)   | 123 (45.90)             | 122 (45.69)                       | 50 (38.17)                       |
| Male                                    | 371 (55.71)   | 145 (54.10)             | 145 (54.31)                       | 81 (61.83)                       |
| Hypertension, n (%)                     | 296 (44.44)   | 120 (44.78)             | 109 (40.82)                       | 67 (51.15)                       |
| CHD, n (%)                              | 75 (11.26)    | 22 (8.21)               | 33 (12.36)                        | 20 (15.27)                       |
| Diabetes, n (%)                         | 128 (19.22)   | 46 (17.16)              | 57 (21.35)                        | 25 (19.08)                       |
| COPD, n (%)                             | 11 (1.65)     | 3 (1.12)                | 4 (1.50)                          | 4 (3.05)                         |
| CKD, n (%)                              | 13 (1.95)     | 8 (2.99)                | 3 (1.12)                          | 2 (1.53)                         |
| Severity, n (%)                         |               |                         |                                   |                                   |
| General group                           | 323 (48.50)   | 199 (75.25)             | 89 (33.33)                        | 35 (26.72)                       |
| Severe and critical group               | 343 (51.50)   | 69 (24.75)              | 178 (66.67)                       | 96 (73.28)                       |
| Fever, n (%)                            | 587 (88.14)   | 236 (88.06)             | 246 (92.13)                       | 105 (80.15)                      |
| Cough, n (%)                            | 499 (74.92)   | 198 (73.88)             | 195 (73.03)                       | 106 (80.92)                      |
| Dyspnea, n (%)                          | 365 (54.80)   | 157 (58.58)             | 141 (52.81)                       | 67 (51.15)                       |
| Sputum, n (%)                           | 268 (40.24)   | 100 (37.31)             | 102 (38.20)                       | 66 (50.38)                       |
| Fatigue, n (%)                          | 272 (40.84)   | 96 (35.82)              | 130 (48.69)                       | 46 (35.11)                       |
| Diarrhea, n (%)                         | 179 (26.88)   | 73 (27.24)              | 81 (30.34)                        | 25 (19.08)                       |
| Myalgia, n (%)                          | 143 (21.47)   | 54 (20.15)              | 64 (23.97)                        | 25 (19.08)                       |
| Hospitalization time, days, median (IQR)| 22 (14–30)    | 23 (16–32)              | 21 (14–28)                        | 19 (11.5–27.5)                   |
| Oxygen supply duration, days, median (IQR)| 15 (6–23)    | 15 (7–24)               | 14 (6–23)                         | 11 (4–21)                        |
| Ventilation model, n (%)                |               |                         |                                   |                                   |
| Non-invasive ventilation                | 514 (82.24%)  | 214 (85.26%)            | 205 (81.67%)                      | 95 (77.24%)                      |
| Invasive ventilation                   | 111 (17.76%)  | 37 (14.74%)             | 46 (18.33%)                       | 28 (22.76%)                      |
| Outcomes                                |               |                         |                                   |                                   |
| Discharge                               | 473 (71.02)   | 203 (75.75)             | 189 (70.79)                       | 81 (61.83)                       |
| Death                                   | 193 (28.98)   | 65 (24.25)              | 78 (29.21)                        | 50 (38.17)                       |
| Lymphocyte percent, median (IQR)        | 8.20 (3.30–14.40) | 8.75 (4.05–15.03)     | 7.70 (3.10–13.75)                 | 7.10 (2.93–15.98)                |
| CRP mg/l, median (IQR)                  | 79.35 (34.13–150.53) | 69.30 (31.00–126.20) | 87.30 (39.80–160.70)              | 84.30 (26.58–151.65)             |
| Response to Corticosteroid therapy, n (%)|               |                         |                                   |                                   |
| Response                                | 260 (39.03)   | 103 (38.43)             | 108 (40.45)                       | 49 (37.40)                       |
| Non-response                            | 406 (60.96)   | 165 (50.57)             | 159 (59.55)                       | 82 (62.60)                       |

Abbreviation: IQR, interquartile ranges; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CRP, C reactive protein.

analysis (Supplementary Figure 1B). Features before (Supplementary Figure 2A, 2C) and after (Supplementary Figure 2B, 2D) imputation were provided in SF and OV, respectively.

LASSO logistic regression finally identified two most informative features (lymphocyte percent, CRP) for model development (Figure 1A). Lymphocyte percent was positively correlated (0.0227) with the response to corticosteroid therapy, while CRP was accompanied by a negative correlation (−0.0037) with the response to corticosteroid therapy (Figure 1B). Since lymphocyte percent was an indicator of immune status and CRP was one of the most sensitive markers of inflammation in various diseases [31, 32], it suggested that the predictive markers selected by LASSO were theoretically closely related to corticosteroid therapy.

Model performance

In general, all five models (LR, SVM, GBDT, KNN, and NN) showed similar and promising corticosteroid therapy response prediction performance across cohorts (Table 2). The AUC was 0.740 with LR, 0.744 with
### Table 2. Performance for prediction of response to corticosteroid therapy of models in different cohorts.

| Model  | Internal validation cohort | External validation cohort |
|--------|---------------------------|----------------------------|
|        | AUC (95% CI)  | Accuracy (95% CI) | SN (95% CI)  | SP (95% CI)  | PPV (95% CI) | NPV (95% CI) | Kappa | F1 | Brier |
| LR     | 0.810 (0.759–0.861) | 0.670 (0.611–0.727) | 0.444 (0.349–0.543) | 0.824 (0.756–0.880) | 0.632 (0.513–0.739) | 0.686 (0.615–0.751) | 0.282 | 0.522 | 0.179 |
| SVM    | 0.809 (0.758–0.859) | 0.6854 (0.626–0.741) | 0.370 (0.279–0.469) | 0.899 (0.842–0.941) | 0.714 (0.578–0.827) | 0.678 (0.601–0.740) | 0.292 | 0.488 | 0.188 |
| GBDT   | 0.803 (0.751–0.855) | 0.730 (0.673–0.783) | 0.694 (0.598–0.780) | 0.755 (0.680–0.819) | 0.658 (0.563–0.744) | 0.784 (0.711–0.847) | 0.445 | 0.676 | 0.180 |
| KNN    | 0.784 (0.731–0.837) | 0.704 (0.645–0.758) | 0.519 (0.420–0.616) | 0.830 (0.763–0.885) | 0.675 (0.563–0.774) | 0.717 (0.647–0.781) | 0.362 | 0.586 | 0.192 |
| NN     | 0.804 (0.753–0.854) | 0.700 (0.642–0.755) | 0.676 (0.579–0.763) | 0.717 (0.640–0.786) | 0.619 (0.525–0.707) | 0.765 (0.689–0.831) | 0.387 | 0.646 | 0.180 |
| PRCTC  | 0.810 (0.760–0.861) | 0.738 (0.681–0.790) | 0.685 (0.589–0.771) | 0.774 (0.701–0.836) | 0.673 (0.577–0.759) | 0.783 (0.711–0.845) | 0.457 | 0.679 | 0.177 |

Abbreviation: AUC, area under the curve; LR, logistic regression; SVM, supported vector machine; GBDT, gradient boosted decision tree; KNN, k-nearest neighbor; NN, neural network; PRCTC, prediction of response to corticosteroid therapy in COVID-19 patients; SN, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval.

SVM, 0.812 with GBDT, 0.808 with KNN, and 0.747 with NN for the training cohort (Figure 2A). The AUC was 0.810 with LR, 0.809 with SVM, 0.803 with GBDT, 0.784 with KNN, and 0.804 with NN for the internal validation cohort (Figure 2B). The AUC was 0.808 with LR, 0.812 with SVM, 0.842 with GBDT, 0.787 with KNN, and 0.810 with NN for the external validation cohort (Figure 2C). Then we have tried various permutations of the baseline models with different voting weights and found that the ensemble model PRCTC (prediction of response to corticosteroid therapy in COVID-19 patients) derived from GBDT, NN, and LR achieved the best predictive performance. The relative importance of features included in models is shown in Supplementary Figure 3.

For the training cohort, PRCTC displayed an AUC of 0.803 (95% CI 0.752–0.854) in predicting the response to corticosteroid therapy (Figure 2A). For the internal validation cohort, PRCTC achieved an AUC of 0.810 (95% CI 0.760–0.861) to predict the response to corticosteroid therapy in COVID-19 patients with an accuracy of 0.738 (95% CI 0.681–0.790) (Figure 2B). For the external validation cohort, PRCTC demonstrated an AUC of 0.845 (95% CI 0.779–0.911) and an accuracy of 0.771 (95% CI 0.690–0.840) (Figure 2C).

The calibration curves of PRCTC in two validation cohorts were depicted in Figure 3, showing that PRCTC displayed the minimal Brier score of 0.177 (intercept 0.375, slope 0.829) for the internal validation cohort (Figure 3A) and 0.156 (intercept 0.216, slope 1.007) for external validation cohort (Figure 3B). As a result, no further modifications of models were performed. Figure 3C–3D further illustrated the ensemble predicted probability distribution on ground-truth no-response and response patients in internal validation and external validation cohort, respectively.

### DISCUSSION

The management of COVID-19 patients remains the top priority in areas where the virus is raging since vaccinations are likely to take years to reach full coverage and may not protect against new variants. Though corticosteroid has been proved to be one of the...
few effective drugs for COVID-19 patients, the population who would benefit from corticosteroid therapy remains unclear. The key to solving this clinical challenge is timely and precisely identifying COVID-19 patients who may respond to corticosteroid therapy in the context of limited medical resources. In this study, we developed and validated an ensemble model named PRCTC, derived from LR, GBDT, and NN, which achieved the best performance in prediction among all the integrated models to predict the response to corticosteroid therapy based on lymphocyte percent and CRP at admission. By calculating the inputted values of CRP and lymphocyte percentage, the model will output the probability of response to corticosteroid therapy. Patients with predictive probability larger or equal to 0.5 were considered as responders to corticosteroid therapy. Otherwise, patients were considered as non-responders. Surprisingly, the model performed an AUC of 0.810 in the internal validation cohort and 0.845 in the external validation cohort. With this model, clinicians could make a prompt and precise medical decision on whether to apply corticosteroids to COVID-19 patients and therefore prevent unneeded patients from side effects of corticosteroid therapy.

The two selected features were reliable in this prediction model. Lymphocyte percent and CRP have been reported to be associated with the severity and outcome of COVID-19 [33, 34]. Decreased lymphocyte percent and elevated CRP are universal in patients with COVID-19, especially in critical patients [35]. In this study, increased lymphocyte percent was positively correlated with the response to corticosteroid therapy while elevated CRP was negatively correlated with response to corticosteroid therapy. The results were consistent with the conclusions of previous studies about corticosteroid therapy in critical patients with other diseases. The Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial demonstrated that hydrocortisone infusion in sepsis patients subjected to mechanical ventilation did not reduce the mortality compared with that of patients receiving standard care and placebo. What’s more, the mortality in this clinical trial was close to the mortality of critically ill patients with COVID-19 [36, 37]. Some other systematic reviews and meta-analyses also did not recommend corticosteroid use for sepsis [38–40]. Given the fact that the pathophysiology of sepsis, characterized by cytokine release, systemic inflammation, lymphopenia, and following immunosuppression, is similar to that of COVID-19 to a certain extent [41, 42], we have reason to believe the reliability of two selected features in our model. Additionally, Ebisawa et al. uncovered that lower CRP predicted stronger corticosteroid responsiveness in multicentric Castleman’s disease with unknown mechanisms [43]. Considering the immunomodulatory and anti-inflammatory functions of corticosteroid [44], the effects of corticosteroid may depend on the function of immune system. And an extremely high level of CRP usually indicates an extremely dysfunctional immune system that cannot be redressed by corticosteroid. However, the exact mechanism is urgent to be investigated in further study. Interestingly, it is lymphocyte percent but not lymphocyte count that is associated with the response of CRP

Figure 2. PRCTC achieved a prompt performance in evaluation on the validation datasets. (A-C) showed ROC curve and AUC of SVM, LR, GBDT, KNN, and NN in training cohort, internal validation cohort, and external validation cohort, respectively. Abbreviations: PRCTC, prediction of response to corticosteroid therapy in COVID-19 patients; ROC, receiver operating characteristic curve; AUC, area under the curve; SVM, supported vector machine; LR, logistic regression; GBDT, gradient boosted decision tree; KNN, k-nearest neighbor; NN, neural network.
corticosteroid therapy. Lymphocyte percentage is the proportion of lymphocytes to white blood cells. Its level is determined not only by lymphocyte count, but also by the number of other types of white blood cells such as neutrophil granulocytes, eosinophil granulocytes, basophilic granulocytes, and monocyte. Furthermore, due to the individual differences in white blood cell count, lymphocyte percentage is a better indicator of immune status than lymphocyte count. Studies also revealed decreased lymphocyte percentage but not lymphocyte count was an independent poor prognostic factor in advanced cancers [45, 46], which reinforced the superiority of lymphocyte percentage. Based on the results of previous studies above, we believe the two features included in PRCTC are clinically reliable for prediction.

Until December 10, 2021, the highly contagious delta variant of SARS-CoV-2 has quickly spread around the world [47]. Its high contagiousness was mostly attributed to the mutations of spike protein [48]. Though the delta variant has been shown to have a 108%

Figure 3. Calibration curves of PRCTC model were shown in validation cohorts. Calibration curves of PRCTC model were shown for internal validation cohort (A) and external validation cohort (B), respectively. The triangle represents the observation group. Each group contained an average of 20 observations. The dashed line is the datum line. The bottom vertical lines refer to the predicted probability distribution. The red curve is the fitted nonparametric calibration curve. PRCTC predicted probability distribution on ground-truth non-response and response patients were shown in internal validation (C) and external validation cohort (D), respectively. Abbreviations: PRCTC, prediction of response to corticosteroid therapy in COVID-19 patients.
increase in hospitalization risk, 235% increase in ICU admission and 133% higher chance of death than the original variant, the pathophysiology of the delta variant and the original variant was similar, characterized by elevated serum levels of cytokines and decreased the count of lymphocyte, and the status of the disease was reflected on the levels of the immune/inflammatory indicators [49]. Besides, a massive vaccination campaign has begun since December 2020. Several studies have reported various vaccines could decrease the transmission of SARS-CoV-2 among the population and prevent the disease from progressing into critical illness by pre-activating the immune system [50–52]. Though we have no idea how the vaccines impact the immune/inflammatory indicators of patients with COVID-19, its effect on the pre-activation of the immune system is universally recognized. And the effect on the immune system will be manifested by the levels of immune/inflammatory indicators, and these are what we are concerned about during the development of this prediction model. In summary, we think our prediction model still works when confronted with the specific population of COVID-19 patients. Given the fact that the SARS-CoV-2 was sporadic in China now, we have little data for further validation in this study. But our research provided a primary model to do such work in the further large-scale, prospective investigation.

There were several advantages of PRCTC. First, this model could be widely applied with great universality. The two features considered in this model were routinely monitored in the process of management of COVID-19 patients, which meant the selected features were easily accessible, even in community medical institutions. Thus, PRCTC could be widely accepted and applied in hospitals with different levels. More importantly, PRCTC had strong scalability of the application. We adopted various types of classification algorithms in the development of PRCTC, which enabled the model to deal with various and complex data. Based on the inside algorithms of the model, PRCTC could potentially extend to other diseases for patient management, including diagnosis, treatment, and prognostic prediction after fine-tuning.

In addition, to our knowledge, PRCTC is the first model so far to enable decision-making on precise corticosteroid use in COVID-19, though numerous computational prediction models were developed for discovering and repurposing suitable drugs, prediction for disease severity and prognosis in the context of COVID-19 [17, 18, 24, 25]. Zhang et al. built a protein 3D model according to the virus RNA, and then performed a screen of mass chemical compounds to identify protein-ligand interacting pairs [17]; Beck et al. developed an artificial intelligence model to predict binding affinity between antiviral drugs approved by Food and Drug Administration and target proteins [18]. These models predicted potential drugs based on the structure of proteins and drugs but still could not precisely recognize the targeted population. In this study, we firstly established a machine learning model named PRCTC to identify the patients benefitting from corticosteroid therapy by involving lymphocyte percent and CRP, which could help the precise medical decision on corticosteroid use in particular patients.

However, there are still some limitations in our research. First, the model achieved promising but moderate AUCs in the internal and external validation cohorts, which may attribute to the limited number of patients in our study. Second, some immune-inflammatory parameters missing in ≥20% of the population did not enter the training process due to the retrospective nature of the study. Third, the types, dosage, and duration of corticosteroid therapy were not considered in this study, given the limited number of patients in each cohort. Thus, a large-scale, prospective investigation is urgent to be designed to refine our study.

CONCLUSIONS

To conclude, in this multicenter, retrospective study, PRCTC was proposed with robustness, universality, and scalability that enabled accurately and timely identifying COVID-19 patients benefit from corticosteroid therapy. However, these findings warrant further investigation.

AUTHOR CONTRIBUTIONS

YG and XMX designed the study. LXC did the analysis. XMX, XFJ, and YY interpreted the data. YG, XMX, and XFJ wrote the manuscript. JHC, XFJ, and YY provided and double-checked clinical data. QLG, SCL, and WZ advised on the conception and design of the study. All authors reviewed the manuscript and approved the final version for submission.

ACKNOWLEDGMENTS

We thank all the people fighting against COVID-19.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This work was supported by the Natural Science Foundation of China [81974405, 81572570].
Editorial note

*This corresponding author has a verified history of publications using a personal email address for correspondence.

REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5:536–44. https://doi.org/10.1038/s41564-020-0695-z PMID: 32123347

2. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. 2021.

3. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cer Mandela, T, Falter M, El Jammal T, Walzer T, François B, Sève P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19:102567. https://doi.org/10.1016/j.autrev.2020.102567 PMID: 32376392

4. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B, Sève P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19:102567. https://doi.org/10.1016/j.autrev.2020.102567 PMID: 32376392

5. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J. Coronavirus infections and immune responses. J Med Virol. 2020; 92:424–32. https://doi.org/10.1002/jmv.25685 PMID: 31981224

6. Tufan A, Avanoğlu Güler A, Maturic-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antiinflammatory drugs. Turk J Med Sci. 2020; 50:620–32. https://doi.org/10.3906/sag-2004-168 PMID: 32299202

7. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395:473–5. https://doi.org/10.1016/S0140-6736(20)30317-2 PMID: 32043983

8. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395:683–4. https://doi.org/10.1016/S0140-6736(20)30361-5 PMID: 32122468

9. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, et al, and RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384:693–704. https://doi.org/10.1056/NEJMoA2021436 PMID: 32678530

10. Sterne JA, Murphy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LC, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, et al, and WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA. 2020; 324:1330–41. https://doi.org/10.1001/jama.2020.17023 PMID: 32876694

11. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020; 133:1039–43. https://doi.org/10.1097/CM9.0000000000000774 PMID: 32118639

12. Arabi YM, Mandourah Y, Al-Hameed F, Sindhi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, et al, and Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018; 197:57–67. https://doi.org/10.1164/rccm.201706-1172OC PMID: 29161116

13. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019; 23:99. https://doi.org/10.1186/s13054-019-2395-8 PMID: 30917856

14. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81:e13–20. https://doi.org/10.1016/j.jinf.2020.03.062 PMID: 32283144

15. Cai J, Li H, Zhang C, Chen Z, Liu H, Lei F, Qin JJ, Liu YM, Zhou F, Song X, Zhou J, Zhao YC, Wu B, et al. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metab. 2021; 33:258–69.e3.
16. Abd-Alrazaq A, Alajiani M, Alhuwail D, Schneider J, Al-Kuwaiti S, Shah Z, Hamdi M, Housse M. Artificial Intelligence in the Fight Against COVID-19: Scoping Review. J Med Internet Res. 2020; 22:e20756. doi:10.2196/20756
PMID:3284779

17. Zhang H, Saravanan KM, Yang Y, Hossain MT, Li J, Ren X, Pan Y, Wei Y. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov. Interdiscip Sci. 2020; 12:368–76. doi:10.1007/s12539-020-00376-6
PMID:3248835

18. Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020; 18:784–90. doi:10.1016/j/csbi.2020.03.025
PMID:32280433

19. Diagnosis and treatment program of 2019 novel coronavirus pneumonia (Trial Version 7). http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm. 2020.

20. Xiong X, Jiao X, Li H, Zeng S, Wang Y, Gao Q. Glucocorticoid benefits the ventilatory function of severe/critical COVID-19 patients. J Infect. 2021; 82:e33–5. doi:10.1016/j.jinf.2020.11.017
PMID:33220384

21. Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012; 28:112–8. doi:10.1093/bioinformatics/btr597
PMID:22039212

22. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo H, et al, and China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020; 180:1081–9. doi:10.1001/jamainternmed.2020.2033
PMID:32396163

23. Hastie T, Qian J. Glmnet vignette. 2014. http://www.web.stanford.edu/~hastie/Papers/Glmnet_Vignette.pdf. 2020.

24. Gao Y, Chen L, Zeng S, Feng X, Chi J, Wang Y, Li H, Jiang T, Yu Y, Jiao X, Liu D, Feng X, Wang S, et al. CIRPMC: An online model with simplified inflammatory signature to predict the occurrence of critical illness in patients with COVID-19. Clin Transl Med. 2020; 10:e210. doi:10.1002/ctm.2.210 PMID:33135353

25. Gao Y, Cai YG, Fang W, Li HY, Wang SY, Chen L, Yu Y, Liu D, Xu S, Cui PF, Zeng SQ, Feng X, Yu RD, et al. Machine learning based early warning system enables accurate mortality risk prediction for COVID-19. Nat Commun. 2020; 11:5033. doi:10.1038/s41467-020-18684-2
PMID:33024092

27. Chauhan VK, Dahiya K, Sharma A. Problem formulations and solvers in linear SVM: a review. Artificial Intelligence Review. 2019; 52:803–55.

28. Jimenez M, Campillo NE, Canelles M. COVID-19 Vaccine Race: Analysis of Age-Dependent Immune Responses against SARS-CoV-2 Indicates that more than Just One Strategy May Be Needed. Curr Med Chem. 2021; 28:3964–79. doi:10.2174/0929867327666202107153123
PMID:33109026

29. Bashash D, Abolghasemi H, Naseri P, Cheraghlai AM, Soltanpoor MJ, Imani Fooladi AA. The Association of Age, Sex, and RT-PCR Results with the Lymphocyte and Neutrophil Counts in SARS-CoV-2 Infection: A Cross-sectional Analysis of 1450 Iranian Patients with COVID-19. Iran J Allergy Asthma Immunol. 2021; 20:129–39. doi:10.18502/ijaai.v20i2.6046
PMID:33904671

30. Vakili S, Savardashtaki A, Jamalnia S, Tabrizi R, Nematoollahi MH, Jafarinia M, Akbari H. Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review. Arch Med Res. 2020; 51:603–7. doi:10.1016/j.arcmed.2020.06.007
PMID:32571605

31. Ji J, Song L, Wang J, Yang Z, Yan H, Li T, Yu L, Jian L, Jiang F, Li J, Zheng J, Li K. Association between urinary per- and poly-fluoroalkyl substances and COVID-19 susceptibility. Environ Int. 2021; 153:106524. doi:10.1016/j.envint.2021.106524
PMID:33773143

32. Moutachakkir M, Lamrani Hanchi A, Baraou A, Boukhira A, Chellak S. Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein. Ann Biol Clin (Paris). 2017; 75:225–9. doi:10.1684/abc.2017.1232
33. Ponti G, Maccaferrì M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020; 57:389–99. https://doi.org/10.1080/10408363.2020.1770685 PMID:28377336

34. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5:33. https://doi.org/10.1038/s41392-020-0148-4 PMID:32296069

35. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B, Li LJ, Zeng G, et al, and China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382:1708–20. https://doi.org/10.1056/NEJMoa2002032 PMID:32109013

36. Venkatesh B, Finer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, et al, and ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018; 378:797–808. https://doi.org/10.1056/NEJMoa1705835 PMID:29347874

37. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8:475–81. https://doi.org/10.1016/S2213-2600(20)30079-5 PMID:32105632

38. Annane D, Bellissant E, Bollaert PE, Briegel J, Confloneri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009; 301:2362–75. https://doi.org/10.1001/jama.2009.815 PMID:19509383

39. Sligl WI, Milner DA Jr, Sundar S, Mphatswe W, Majumdar SR. Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. Clin Infect Dis. 2009; 49:93–101. https://doi.org/10.1086/599343 PMID:19489712

40. Volbeda M, Welterslev J, Gluud C, Zijlstra JG, van der Horst IC, Keus F. Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015; 41:1220–34. https://doi.org/10.1007/s00134-015-3899-6 PMID:26100123

41. Gautret P, Million M, Jarrot PA, Campion-Jau L, Colson P, Fenollar F, Leone M, La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020; 16:1159–84. https://doi.org/10.1080/1744666X.2021.1847640 PMID:33356661

42. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018; 392:75–87. https://doi.org/10.1016/S0140-6736(18)30696-2 PMID:29337192

43. Ebisawa K, Shimura A, Honda A, Masamoto Y, Nakahara F, Kurokawa M. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman’s disease. Leuk Lymphoma. 2021; 62:614–9. https://doi.org/10.1080/10428194.2020.1834094 PMID:33076723

44. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004; 30:261–77. https://doi.org/10.1385/IR:30:3:261 PMID:15531769

45. Yoneyama Y, Ito M, Sugitou M, Kobayashi A, Nishizawa Y, Saito N. Postoperative lymphocyte percentage influences the long-term disease-free survival following a resection for colorectal carcinoma. Jpn J Clin Oncol. 2011; 41:343–7. https://doi.org/10.1093/jjco/hyq223 PMID:21199789

46. Zhao W, Wang P, Jia H, Chen M, Gu X, Liu M, Zhang Z, Cheng W, Wu Z. Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care? BMC Cancer. 2017; 17:514. https://doi.org/10.1186/s12885-017-3498-8 PMID:28768490

47. Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. medRxiv. 2021. [Epub ahead of print]. https://doi.org/10.1101/2021.06.21.21259268 PMID:34845460

48. Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the Delta Variant B.1.617.2 COVID-19. Clin Pract. 2021; 11:778–84. https://doi.org/10.3390/clinpract11040093 PMID:34698149
49. Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, Wu G, Chen R, Zhang Z, Wei D, Du P, Zhang J, Lin P, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct Target Ther. 2021; 6:347. https://doi.org/10.1038/s41392-021-00760-8 PMID:34564690

50. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021; 384:1824–35. https://doi.org/10.1056/NEJMo2034201 PMID:33440088

51. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, et al. SARS-CoV-2 Variants and Vaccines. N Engl J Med. 2021; 385:179–86. https://doi.org/10.1056/NEJMsr2105280 PMID:34161052

52. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, et al, and Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397:99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID:33306989
Supplementary Figure 1. Visualization of the denoising and filtering process. (A) Heatmap of raw lab test data. (B) Heatmap of lab test data after removing lab test features with more than and equal to 20% missing entries across the SF and OV hospitals. Black tiles refer to missing entries. Abbreviations: NK, natural killer; Th, T-helper lymphocyte; Ts, T-suppressor lymphocyte; C3, complement 3; C4, complement 4; CRP, C reactive protein; PCT, procalcitonin; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-2R, interleukin-2 receptor; IL-4, interleukin-4; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; C-IGG SARS-CoV-2 specific antibody IgG; C-IGM SARS-CoV-2 specific antibody IgM; SF, Sino-French New City Campus of Tongji Hospital; OV, Optical Valley Campus of Tongji Hospital.
Supplementary Figure 2. Visualization of the imputation process. (A, C) Heatmap of SF and OV lab test data before imputation. (B, D) Heatmap of SF and OV lab test data after imputation. Black tiles refer to missing entries. Abbreviations: CRP, C reactive protein; PCT, procalcitonin; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-2R, interleukin-2 receptor; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; SF, Sino-French New City Campus of Tongji Hospital; OV, Optical Valley Campus of Tongji Hospital.
Supplementary Figure 3. The importance of relative features derived from PRCTC, GBDT, NN, and LR model, respectively. Abbreviations: PRCTC, prediction of response to corticosteroid therapy in COVID-19 patients; LR, logistic regression; GBDT, gradient boosted decision tree; NN, neural network.
Supplementary Table 1. Data of features before screening in different cohorts.

| Features                          | Total (N=666) | Training cohort (N=268) | Internal validation cohort (N=267) | External validation cohort (N=131) |
|----------------------------------|---------------|-------------------------|-----------------------------------|-----------------------------------|
| NK cell count per μl             | 111.50 (39.50–193.75) | 133.00 (49.00–190.00) | 111.50 (45.75–159.50) | 101.00 (38.00–199.00) |
| NK cell percent, (%)             | 9.84 (6.43–17.57) | 9.34 (5.77–17.79) | 9.84 (7.52–20.73) | 10.28 (6.54–15.73) |
| (Th+Ts) count per μl             | 717.50 (318.25–1045.75) | 700.00 (339.75–1185.00) | 783.75 (362.38–898.25) | 610.00 (284.00–1248.00) |
| (Th+Ts) percent, (%)             | 65.90 (59.50–74.03) | 63.77 (60.71–71.84) | 71.25 (61.55–77.71) | 66.36 (57.86–71.38) |
| Th/Ts                            | 2.15 (1.31–3.26) | 2.50 (1.62–3.26) | 1.71 (1.20–2.47) | 2.18 (1.44–3.39) |
| (T+B+NK) count per μl            | 1039.50 (553.75–1520.63) | 1151.00 (728.00–1701.00) | 1046.00 (620.38–1314.50) | 981.50 (472.00–1805.00) |
| (T+B+NK) percent, (%)            | 99.19 (98.58–99.53) | 99.32 (98.69–99.56) | 99.03 (98.44–99.37) | 99.19 (98.57–99.53) |
| (CD3+CD4+) count per μl          | 413.50 (191.75–632.00) | 415.00 (205.50–736.50) | 378.00 (212.75–546.00) | 425.00 (185.00–715.00) |
| (CD3+CD4+) percent, (%)          | 44.81 (37.03–52.36) | 45.32 (32.44–50.62) | 44.13 (33.13–52.74) | 43.09 (39.17–48.86) |
| (CD3+CD8+) count per μl          | 233.50 (74.50–379.00) | 184.00 (78.50–355.00) | 260.00 (91.50–353.25) | 205.00 (56.00–405.00) |
| (CD3+CD8+) percent, (%)          | 20.48 (13.57–29.85) | 17.93 (14.41–24.36) | 24.45 (16.94–31.80) | 20.42 (12.23–27.29) |
| (CD3+CD19+) count per μl         | 126.00 (66.50–218.50) | 135.00 (86.00–292.00) | 100.50 (46.50–156.50) | 145.00 (72.00–266.00) |
| (CD3+CD19+) percent, (%)         | 15.43 (9.72–26.07) | 18.22 (10.47–28.75) | 12.07 (7.33–19.02) | 17.78 (12.27–22.05) |
| Total T-THS                      | 1.69 (0.68–3.09) | 1.60 (0.74–2.69) | 1.85 (1.14–3.61) | 1.39 (0.47–3.08) |
| (CD3+CD19-) count per μl         | 682.00 (309.00–1061.50) | 680.00 (324.00–1212.00) | 704.50 (372.25–925.25) | 605.00 (274.00–1263.00) |
| (CD3+CD19-) percent, (%)         | 69.96 (57.74–78.32) | 66.52 (56.80–75.60) | 76.08 (62.64–81.80) | 70.06 (60.43–75.94) |
| C3, g/L                          | 0.82 (0.69–0.97) | 0.83 (0.71–0.98) | 0.80 (0.65–0.92) | 0.81 (0.64–1.01) |
| C4, g/L                          | 0.21 (0.15–0.28) | 0.21 (0.15–0.28) | 0.21 (0.14–0.30) | 0.19 (0.14–0.26) |
| Ferritin μg/L                    | 957.00 (548.45–1841.70) | 917.50 (556.08–1677.95) | 968.50 (548.00–1852.50) | 1166.20 (503.15–2601.00) |
| Lymphocyte count, per μl         | 0.60 (0.38–0.93) | 0.62 (0.40–0.94) | 0.59 (0.35–0.89) | 0.60 (0.37–1.02) |
| Lymphocyte percent, (%)          | 8.20 (3.30–14.40) | 8.75 (4.05–15.03) | 7.70 (3.10–13.75) | 7.10 (2.93–15.98) |
| CRP, mg/L                        | 79.35 (34.13–150.53) | 69.30 (31.00–126.20) | 87.30 (39.80–160.70) | 84.30 (26.58–151.65) |
| PCT, ng/mL                       | 0.11 (0.05–0.45) | 0.09 (0.04–0.27) | 0.10 (0.05–0.53) | 0.19 (0.08–1.48) |
| TNF-α, pg/mL                     | 9.90 (7.50–14.25) | 9.50 (7.10–12.60) | 9.65 (7.68–13.65) | 12.65 (8.43–28.38) |
| IL-1β, pg/mL                     | 5.00 (5.00–5.45) | 5.00 (5.00–5.00) | 5.00 (5.00–5.00) | 5.00 (5.00–11.08) |
| Abbreviation | IL-2R, U/mL | IL-6, pg/mL | IL-8, pg/mL | IL-10, pg/mL | IGA, g/L | IGG, U/L | IGM, U/L | C-IGG, U/L | C-IGM, U/L |
|--------------|------------|-------------|-------------|-------------|----------|---------|---------|----------|---------|
|              | 816.00     | 780.00      | 801.00      | 1061.00     | (494.00–1288.50) | (458.00–1155.00) | (473.00–1336.75) | (570.75–1653.75) | (5.00–13.58) | (5.00–11.15) | (5.00–13.95) | (5.00–20.13) |
|              | 24.83      | 21.03       | 30.38       | 27.47       | (5.19–89.94)     | (5.01–65.39)     | (5.27–89.78)     | (5.77–276.43)    | (10.65–54.70) | (10.00–45.20) | (10.45–48.75) | (13.50–110.25) |
|              | 20.20      | 18.40       | 19.15       | 30.25       | (6.20)           | (5.50)           | (6.90)           | (6.40)       | (5.00–13.58) | (5.00–11.15) | (5.00–13.95) | (5.00–20.13) |
|              | 2.30       | 2.28        | 2.23        | 2.41        | (1.64–2.99)      | (1.63–2.93)      | (1.62–3.09)      | (1.88–3.01)    | (10.30–5.70) | (10.33–15.63) | (10.05–16.08) | (10.90–14.30) |
|              | 12.60      | 12.90       | 12.40       | 12.60       | (0.87)           | (0.90)           | (0.82)           | (0.95)       | (0.63–1.27) | (0.63–1.27) | (0.62–1.29) | (0.62–1.14) |
|              | 181.09     | 177.83      | 181.09      | 188.72      | (181.09)         | (177.83)         | (181.09)         | (188.72)     | (150.49–223.12) | (146.35–205.31) | (157.34–222.06) | (152.19–263.46) |
|              | 61.71      | 55.14       | 50.73       | 93.02       | (26.99–160.88)   | (23.65–148.14)   | (27.57–135.14)   | (44.73–341.40) | (150.49–223.12) | (146.35–205.31) | (157.34–222.06) | (152.19–263.46) |

Abbreviation: IQR, interquartile ranges; NK, natural killer; Th, T-helper lymphocyte; Ts, T-suppressor lymphocyte; C3, complement 3; C4, complement 4; CRP, C reactive protein; PCT, procalcitonin; TNF-α, tumor necrosis factor α; IL-1β, interleukin-1β; IL-2R, interleukin-2 receptor; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; C-IGG SARS-CoV-2 specific antibody IgG; C-IGM SARS-CoV-2 specific antibody IgM.

Footnote: the data of interferon-γ and interleukin-4 was missing in all selected patients, thus, we did not make statistics.
Supplementary Table 2. Baseline clinical characteristics of non-responders and responders to corticosteroid therapy.

| Characteristics          | Non-responders (n=406) | Responders (n=260) | p-value   |
|--------------------------|------------------------|--------------------|-----------|
| Age (years), median (IQR) | 66.5 (57–74)           | 61 (48–67.5)       | <0.0001   |
| Sex, n (%)               |                        |                    | 0.5397    |
| Female                   | 176 (43.35)            | 119 (45.77)        |           |
| Male                     | 230 (56.65)            | 141 (54.23)        |           |
| Hypertension, n (%)      | 198 (48.77)            | 98 (37.69)         | 0.005     |
| CHD, n (%)               | 53 (13.05)             | 22 (8.46)          | 0.0674    |
| Diabetes, n (%)          | 81 (19.95)             | 47 (18.08)         | 0.5494    |
| COPD, n (%)              | 9 (2.22)               | 2 (0.77)           | 0.1528    |
| CKD, n (%)               | 7 (1.72)               | 6 (2.31)           | 0.5954    |
| Fever, n (%)             | 359 (88.42)            | 228 (87.69)        | 0.7758    |
| Cough, n (%)             | 314 (77.34)            | 185 (71.15)        | 0.0724    |
| Dyspnea, n (%)           | 236 (58.13)            | 129 (49.62)        | 0.0313    |
| Sputum, n (%)            | 175 (43.10)            | 93 (35.77)         | 0.0597    |
| Fatigue, n (%)           | 167 (41.13)            | 105 (40.38)        | 0.8480    |
| Diarrhea, n (%)          | 108 (26.60)            | 71 (27.31)         | 0.8409    |
| Myalgia, n (%)           | 91 (22.41)             | 52 (20.00)         | 0.4593    |
| Oxygen supply duration*, days, median (IQR) | 26 (17–32) | 14 (6–18) | <0.0001 |
| Hospitalization time*, days, median (IQR) | 33 (28–38) | 20 (17–24) | <0.0001 |

Abbreviation: IQR, interquartile ranges; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.
Footnote: *We excluded dead patients when calculated the Oxygen supply duration and Hospitalization time of Non-responders and Responders.